ID | 1356 |
Name of the vaccine | Tritanrix-HepB/Hib |
Microbe | Bacteria |
Disease name | Haemophilus influenzae type b (Hib) |
Name of bacteria | Haemophilus influenzae |
Type of vaccine | Combination |
Nucleic acid content | DNA |
Age | 50 to 71 days |
Description of the vaccine | Pentavalent combination vaccine. |
Name of the manufacturer | Sanofi Pasteur, a Sanofi Company |
Name of the manufacturing country | Mexico, Peru |
Year of manufacture | 2008 |
Clinical Phase status | Clinical - Phase 3 |
Bacterial strain | Anaerobic gram-negative coccobacillus. |
Efficacy | NA |
Vaccine formulation | Suspension for injection |
Dosage | Three doses of 0.5 mL given at age 2, 4, and 6 months. |
Mechanism of action | NA |
Route of administration | Intramuscular |
Indications | NA |
Export | NA |
Approval | NA |
Adjuvant | NA |
Repurposing | For pertussis, tetanus, hepatitis B and diphtheria. |
Side effects of vaccine | NA |
Post vaccination | NA |
Dose type | Combination (3 doses) |
Interspecies transfer | NA |
PubMed identifier | NA |
Clinical trial number | NCT00313911 |
Reference | https://www.vaccinebox.com/product/tritanrix-hb-hib/ |
Other name | NA |
Additional Links | NA
|